Clinical trial with Oficina da Lembranca, a cognitive stimulation with computers, and biomarkers of neuroplasticity and neurodegeneration concentration.
In amyotrophic lateral sclerosis, there is a need for biomarkers to distinguish patients from controls, to follow disease progression and to provide information about the pathogenesis of disease. In a
Additional file 7: Table S6. The AD upregulated DEGs, downregulated DEGs, and the GO pathway analyses of those DEGs in our Visium SRT dataset. We also include the 14 published AD-related gene lists, t
